BeiGene (BGNE) reported quarterly earnings results on Wednesday, May-11-2016. The company reported $-0.97 earnings per share for the quarter, missing the analyst consensus estimate by $-0.34. Analysts had a consensus of $-0.63. The company posted revenue of $.70 million in the period, compared to analysts expectations of $1.65 million. The company’s revenue was down -50.0% compared to the same quarter last year.
Many Wall Street Analysts have commented on BeiGene. Robert W. Baird Initiated BeiGene on Feb 29, 2016 to “Outperform”, Price Target of the shares are set at $44.Goldman Initiated BeiGene on Feb 29, 2016 to “Buy”, Price Target of the shares are set at $33.BeiGene was Initiated by Morgan Stanley to “Overweight” on Feb 29, 2016.
In a different news, on Feb 9, 2016, Howard Liang (CFO) purchased 65,000 shares at $1.85 per share price. According to the SEC, on Feb 9, 2016, Ruirong Yuan (Chief Medical Officer) purchased 130,000 shares at $1.85 per share price.